Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
22 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Sperimentazione conclusa
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome (Phase II-III) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
GRADIENT: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant - AT
Institution: Information not provided - AT
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
ACSPIRE: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor -FR
Institution: Information not provided - FR
GERMANIA
Bayern
WÜRZBURG
ACSPIRE: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor -DE
Zentrum Innere Medizin (ZIM)
Medizinische Klinik und Poliklinik I - Endokrinologie und Diabetologie
ITALIA
TOSCANA
PISA
ACSPIRE: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor - IT
Azienda Ospedaliero Universitaria Pisana - Ospedale Cisanello
U.O. Endocrinologia 2
PAESI BASSI
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat (Phase 2) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
GRACE: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome: A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - AT
Institution: Information not provided - AT
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease - BE
Universitair Ziekenhuis Brussel
Endocrinologie
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome (Phase III) - FR
Institution: Information not provided - FR
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio di fase III in aperto finalizzato alla valutazione della sicurezza e dell'efficacia di COR-003 (2S, 4R-ketoconazolo) nel trattamento della sindrome di Cushing endogena - IT
Institution: Information not provided - IT
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio in aperto di fase I/II per valutare la sicurezza, la tollerabilità e l'efficacia preliminare di durvalumab in monoterapia o in combinazione con tremelimumab in pazienti pediatrici con tumori solidi avanzati e neoplasie ematologiche
Institution: Information not provided - IT
ITALIA
LAZIO
ROMA
Studio in aperto, a braccio singolo, di fase 1/2 che valuta la sicurezza e l'efficacia di Ponatinib per il trattamento delle leucemie ricorrenti o refrattarie o dei tumori solidi in pazienti pediatrici
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
GRACE: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome: A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant -ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome -ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
GRADIENT: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant -ES
Institution: Information not provided - ES
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
Sperimentazioni cliniche internazionali
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
ACSPIRE: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor.
Institution: Information not provided - US
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
GRACE: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome: A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant
Institution: Information not provided - US
SVEZIA
Region Stockholm
ADDRESS: NOT PROVIDED - SE
An open label study to asses the safety and efficacy of COR-003 (2S, 4R-Ketoconazole) in the treatment of endogenous Cushing's syndrome (phase III)
Institution: Information not provided - SE
SVIZZERA
Suisse Romande
ADDRESS: NOT PROVIDED - CH